Patients. Science. Passion.
Ascendis Pharma (ascendispharma.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 53rd percentile of 10970 Healthcare brands.
Ascendis Pharma is a biopharmaceutical company headquartered in Copenhagen, Denmark, founded in 2007. It develops innovative therapies using its proprietary TransCon technology platform, focusing on Endocrinology Rare Disease and Oncology. The company aims to improve safety, efficacy, tolerability, and convenience of treatments for patients, caregivers, and healthcare professionals, positioning itself as a fully integrated global biopharma company guided by the values of Patients, Science, and Passion.
| Brand Name | Ascendis Pharma |
|---|---|
| Domain | ascendispharma.com |
| Industry | Healthcare |
| Founded | 2007 |
| Headquarters | Copenhagen, Denmark |
| Main Competitors | Novo Nordisk (88/100), Pfizer (89/100), Sandoz (87/100), Ipsen (89/100), Novartis (71/100), Amgen (90/100), Genentech (84/100) |
Moz Domain Authority 44/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #696,484 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs." (Meta description: 24 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram; no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Ascendis Pharma?", Claude could identify the brand as of September 2026. Ascendis Pharma is a Danish-American biopharmaceutical company that develops long-acting therapies using its proprietary TransCon drug delivery technology, which extends the duration of action of existing drugs. Its lead products focus on endocrinology and rare diseases, includin Best known for Its TransCon technology platform for creating long-acting prodrug versions of existing therapies, notably in growth hormone and rare endocrine disease treatment.
When asked "Best brands similar to Ascendis Pharma?", Claude would recommend Ascendis Pharma as of September 2026. It's a notable innovator in long-acting biologics and rare disease treatment, so I'd mention it when discussing biopharma companies focused on novel drug delivery platforms.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Ascendis Pharma's main competitors in Healthcare: Novo Nordisk (88/100), Pfizer (89/100), Sandoz (87/100), Ipsen (89/100), Novartis (71/100).
Sources: Brand Analyzer scan
Ascendis Pharma is a biopharmaceutical company headquartered in Copenhagen, Denmark, founded in 2007. It develops innovative therapies through its proprietary TransCon technology platform, focusing on Endocrinology Rare Disease and Oncology.
Sources: Ascendis Pharma official site
Ascendis Pharma has limited AI-search visibility, scoring 38/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 45, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Ascendis Pharma official site
Ascendis Pharma was founded in 2007. Ascendis Pharma operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Ascendis Pharma develops and delivers innovative therapies using its TransCon technology platform, aiming to improve the safety, efficacy, tolerability, and convenience of treatments for patients with endocrine rare diseases and cancer.
Sources: Ascendis Pharma official site
Ascendis Pharma scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Ascendis Pharma official site
Ascendis Pharma can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Ascendis Pharma official site
Ascendis Pharma offers therapies developed through its TransCon technology platform, targeting conditions within Endocrinology Rare Disease and Oncology. These therapies are designed to improve safety, efficacy, tolerability, and convenience for patients.
Sources: Ascendis Pharma official site
Ascendis Pharma is known for its proprietary TransCon technology platform, which it uses to create advanced therapies in Endocrinology Rare Disease and Oncology, aiming to address unmet medical needs with improved treatment profiles.
Sources: Ascendis Pharma official site
Ascendis Pharma's therapies and platform are used by patients and caregivers affected by endocrine rare diseases and oncology conditions, as well as healthcare professionals who administer or prescribe its treatments, and pharmaceutical industry partners who collaborate on its technology.
Sources: Ascendis Pharma official site
Ascendis Pharma scores 38/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Ascendis Pharma has a weak AI-visibility profile at 38/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (26/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #696,484 (Tranco) and a Moz Domain Authority of 44/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Ascendis Pharma from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Ascendis Pharma: Arine (77/100), Alexandria Real Estate Equities (Alexandria®) (77/100), Ascensia Diabetes Care (77/100), American Society of Consultant Pharmacists (ASCP) (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.